| P50 | author | Grethe Birketvedt | Q11972597 |
| | Ingrid Gause-Nilsson | Q125293071 |
| P2093 | author name string | Serena Tonstad | |
| | Herbert Schuster | |
| | Karl Peter Ohman | |
| | Bjorn Fagerberg | |
| | SIR Study Group | |
| P2860 | cites work | The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. | Q46905943 |
| | Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. | Q51483374 |
| | Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. | Q51553862 |
| | Menopause is associated with reduced protection from postprandial lipemia. | Q51559990 |
| | Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men. | Q51561639 |
| | Postprandial hypertriglyceridemia and insulin resistance in normoglycemic first-degree relatives of patients with type 2 diabetes. | Q51562526 |
| | Black-white differences in postprandial triglyceride response and postheparin lipoprotein lipase and hepatic triglyceride lipase among young men. | Q51562708 |
| | Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. | Q51629788 |
| | Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence. | Q34495378 |
| | Postprandial lipemia--effect of lipid-lowering drugs | Q34666856 |
| | Progression from IGT to type 2 diabetes mellitus: the central role of impaired early insulin secretion | Q35087584 |
| | Post-challenge hyperglycaemia is associated with premature death and macrovascular complications | Q35090492 |
| | Postprandial lipemia and cardiovascular disease | Q35549906 |
| | Mobilisation of enterocyte fat stores by oral glucose in humans. | Q35595712 |
| | What does postprandial hyperglycaemia mean? | Q35685742 |
| | Lipid and lipoprotein dysregulation in insulin resistant states | Q36397461 |
| | Mechanisms of postprandial hyperlipidaemia--remnants and coronary artery disease | Q41578642 |
| | Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial | Q43606926 |
| | Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus. | Q45086355 |
| | The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes | Q45201526 |
| | Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes | Q46406430 |
| | Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. The Atherosclerosis Risk in Communities (ARIC) Study | Q46472081 |
| | Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population | Q46587223 |
| | Ethnic differences in postprandial triglyceride response to a fatty meal and lipoprotein lipase in lean and obese African American and Caucasian women. | Q46881355 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 174-180 | |
| P577 | publication date | 2007-09-01 | |
| P1433 | published in | Diabetes and Vascular Disease Research | Q5270121 |
| P1476 | title | Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARalpha/gamma agonist, tesaglitazar | |
| P478 | volume | 4 | |